These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 18097534

  • 1. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE.
    Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
    [Abstract] [Full Text] [Related]

  • 2. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 3. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.
    Cancer Res; 2003 Jul 15; 63(14):3991-4. PubMed ID: 12873996
    [Abstract] [Full Text] [Related]

  • 4. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 15; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
    Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L.
    Eur Urol; 2005 May 15; 47(5):695-702. PubMed ID: 15826765
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Hsing AW.
    Cancer Epidemiol Biomarkers Prev; 2001 May 15; 10(5):421-7. PubMed ID: 11352850
    [Abstract] [Full Text] [Related]

  • 7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 15; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul 15; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 9. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO, Akanji AO, Mojiminiyi OA, Bashir AA, Daar AS, Varghese R.
    Prostate Cancer Prostatic Dis; 2005 Jul 15; 8(1):84-90. PubMed ID: 15775992
    [Abstract] [Full Text] [Related]

  • 10. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM.
    J Urol; 2005 Dec 15; 174(6):2178-80. PubMed ID: 16280759
    [Abstract] [Full Text] [Related]

  • 11. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004 Dec 15; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 12. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS.
    Cancer; 2005 Jan 01; 103(1):76-84. PubMed ID: 15540247
    [Abstract] [Full Text] [Related]

  • 13. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
    Unsal E, Köksal D, Yurdakul AS, Atikcan S, Cinaz P.
    Respir Med; 2005 May 01; 99(5):559-65. PubMed ID: 15823452
    [Abstract] [Full Text] [Related]

  • 14. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 15. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer.
    Baffa R, Reiss K, El-Gabry EA, Sedor J, Moy ML, Shupp-Byrne D, Strup SE, Hauck WW, Baserga R, Gomella LG.
    Tech Urol; 2000 Sep 01; 6(3):236-9. PubMed ID: 10963500
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb 01; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 17. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M.
    Cancer Epidemiol Biomarkers Prev; 2005 May 01; 14(5):1270-3. PubMed ID: 15894684
    [Abstract] [Full Text] [Related]

  • 18. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2006 Jun 01; 15(6):1137-41. PubMed ID: 16775172
    [Abstract] [Full Text] [Related]

  • 19. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
    Lee SE, Chung JS, Han BK, Park CS, Moon KH, Byun SS, Choe G, Hong SK.
    Eur Urol; 2008 Dec 01; 54(6):1324-32. PubMed ID: 18339472
    [Abstract] [Full Text] [Related]

  • 20. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007 Dec 01; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.